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Abstract
Objective: to determine whether a 4-week postoperative rehabilitation program delivered in Nursing Care Facilities (NCFs)
would improve quality of life and mobility compared with receiving usual care.
Design: parallel randomised controlled trial with integrated health economic study.
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Setting: NCFs, in Adelaide South Australia.
Subjects: people aged 70 years and older who were recovering from hip fracture surgery and were walking prior to hip fracture.
Measurements: primary outcomes: mobility (Nursing Home Life-Space Diameter (NHLSD)) and quality of life
(DEMQOL) at 4 weeks and 12 months.
Results: participants were randomised to treatment (n = 121) or control (n = 119) groups. At 4 weeks, the treatment group
had better mobility (NHLSD mean difference −1.9; 95% CI: −3.3, −0.57; P = 0.0055) and were more likely to be alive (log
rank test P = 0.048) but there were no differences in quality of life. At 12 months, the treatment group had better quality of
life (DEMQOL sum score mean difference = −7.4; 95% CI: −12.5 to −2.3; P = 0.0051), but there were no other differ-
ences between treatment and control groups. Quality adjusted life years (QALYs) gained over 12 months were 0.0063 higher
per participant (95% CI: −0.0547 to 0.0686). The resulting incremental cost effectiveness ratios (ICERs) were $5,545
Australian dollars per unit increase in the NHLSD (95% CI: $244 to $15,159) and $328,685 per QALY gained (95% CI:
$82,654 to $75,007,056).
Conclusions: the benefits did not persist once the rehabilitation program ended but quality of life at 12 months in survi-
vors was slightly higher. The case for funding outreach home rehabilitation in NCFs is weak from a traditional health eco-
nomic perspective.
Trial registration: ACTRN12612000112864 registered on the Australian and New Zealand Clinical Trials Registry. Trial
protocol available at https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id = 361980
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Key points
• A 4-week multidisciplinary postoperative rehabilitation program after hip fracture surgery conducted in nursing care facil-
ities was associated with better mobility and survival at 4 weeks compared with usual care.
• The benefits did not persist once the rehabilitation program ended but a small gain in quality of life at 12 months in survi-
vors was seen.
• The overall mortality rate was 46% at 12 months.
• The outreach rehabilitation program could not be considered cost-effective against current public funding thresholds.
• Future trials should explore different approaches to postoperative hip fracture recovery in this group, such as nursing care
facility based rehabilitation approaches.
Background
Hip fractures are a common cause of suffering for residents
of nursing care facilities (NCFs) and outcomes are poor [1].
Most residents have dementia and are frail. In a retrospect-
ive cohort study of 60,111 US Medicare beneficiaries living
in nursing homes, only one in five patients who had been
fully independent or required limited supervision/assistance
walking at baseline survived to regain their pre-fracture
level of walking 180 days after fracture [2].
Guidelines for hip fracture management promote
prompt surgery, early mobilisation, and a team-based
rehabilitation approach to restoring function and mobility
[3]. The high risk of death and adverse outcomes means
there is uncertainty about the benefits of health service
resources allocated to rehabilitation in people living in
NCFs [3]. We investigated the feasibility of providing a
Comprehensive Geriatric Assessment and interdisciplinary
rehabilitation program which was developed according to
clinical guidelines [4, 5]. The aim of the study was to exam-
ine if a rehabilitation program in NCFs for people who
were recovering from hip fracture surgery improved quality
of life and mobility at 4 weeks and 12 months.
Methods/design
See Supplementary material, available at Age and Ageing
online for the CONSORT checklist and protocol. The
study was approved by the Southern Adelaide Clinical
Human Research Ethics Committee. A randomised con-
trolled trial with masked outcome assessments was under-
taken between June 2012 and December 2014. A computer
generated random sequence with random block sizes was
used by a pharmacist external to the project to allocate peo-
ple with a hip fracture, who had been treated surgically into:
(a) 4-week ambulatory geriatric rehabilitation program
(delivered in the NCF) (b) usual care. Recruitment occurred
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on acute orthopaedic wards at three South Australian
Hospitals.
Participant procedures
Participants were randomised in hospital, the intervention
commenced within 24 h of return to the NCF, and on
return all residents received usual medical care from their
general practitioner. All hospitals had an Orthogeriatrics
service that reviewed patients prior to discharge. Inclusion
criteria were: a recent hip fracture treated surgically, aged 70
years or older, able to follow a one-step command, living in
an NCF prior to injury, ambulant prior to fracture, and
ready for discharge, providing self or proxy informed con-
sent (full criteria listed in Supplementary material, available
at Age and Ageing online).
Those allocated to the intervention received visits from
a hospital outreach team who provided a Comprehensive
Geriatrics Assessment, physiotherapy and nutritional assess-
ment and care plan. Physiotherapy included mobility and
task specific training, graduated muscle strengthening exer-
cises and training of care staff and family. The geriatrician
met families within a fortnight to discuss progress. The
intervention was low intensity and involved 13 h of input.
Measurements/procedures
Primary outcomes
The primary outcomes were mobility autonomy (measured
using the Nursing Home Life-Space Diameter (NHLSD))
and Quality of Life. The NHLSD has high intra-rater (0.922)
and inter-rater (0.951) reliability and moderate positive correl-
ation with other functional characteristics (e.g. social activity
participation, dressing,) [6]. It consists of four diameters
scored on a scale of 0–5 and weighted, with possible scores
ranging from 0 (bed- or chair-bound) to 120 (signifying leav-
ing the facility daily). Care staff were asked to describe the
level of independence and hands-on support each participant
was receiving at baseline, 4 weeks and 12 months.
Quality of life was assessed with the 28-item
DEMQOL and 31-item DEMQOL-Proxy which are con-
dition specific measures designed to measure health-
related quality of life for older people with dementia and
their carers [7]. At baseline 90 participants completed the
DEMQOL and 237 were completed by proxies (in 83
cases both an individual and proxy questionnaires were
completed). At 4 weeks, the DEMQOL-Proxy was com-
pleted for 199 participants. The overall correlation
between scores of the self-completed questionnaires and
proxy questionnaires was poor at baseline (r = 0.27538, P
= 0.0117) with proxies tending to score quality of life low-
er than individuals suggesting that different constructs
were being measured. Where two questionnaires were
available the DEMQOL-Proxy was used. The EuroQol
five dimension–five level questionnaire (EQ-5D-5L) was
administered to compare participants’ quality of life with
other patient groups internationally [8].
Secondary outcomes
Physical dependency was measured by the Modified Barthel
Index [9] and the Functional Recovery Scale [10]. Other mea-
sures included cognition (Mini-Mental State Examination:
MMSE) [11], confusion or delirium (Confusion Assessment
Method) [12], depression (Cornell Scale for Depression in
Dementia) [13], pain (the Pain Assessment In Advanced
Dementia scale: PAINAD) [14] and nutrition (The Mini-
Nutritional Assessment) [15].
Statistical analysis
To assess minimally important differences in the DEMQOL
index score, we needed 98 per group (intervention and con-
trol). After allowing for deaths and drop-outs of 20% the
estimated sample size was 196*1.2 = 236 (118 per group).
The detectable effect size between groups was conservatively
selected as small to medium (0.10–0.25) as suggested by
Cohen [16]. Calculations were based on two-tailed tests with
power of at least 80% and significance level of 0.05.
Outcomes were evaluated using linear mixed models
with a time-by-group interaction term. The covariates were
group, time, time*group and baseline scores for the out-
come variables.
To investigate survival from the randomisation to 4
weeks and 12 months, we used Kaplan–Meier and log rank
test to test the between group difference. All data were ana-
lysed according to the intention-to-treat principle and per-
formed with SAS, v9.3 (SAS institute) and R 3.11.
To assess the incremental cost-effectiveness of the inter-
vention compared with usual care we examined incremental
cost-effectiveness per unit increase in the NHLSD total score
over 1-year follow-up. Utility-based outcomes were incorpo-
rated into the analysis, to generate a secondary outcome:
incremental cost per Quality adjusted life year (QALY; based
on DEMQOL-Proxy values). QALYs were calculated using
the area-under-the-curve [17]. Cost effectiveness acceptability
curves (CEACs) were constructed, depicting the probability
of the intervention being more cost-effective compared with
the usual care arm at different willingness-to-pay thresholds
(see Supplementary Figures S4 and S5, available at Age and
Ageing online) [18]. Further details on the cost effectiveness
analysis are provided in the supplementary information.
Results
At the three participating hospitals 2,120 hip fracture
patients were screened, 354 were eligible and following con-
sent 240 participated (see Supplementary Figure S1, avail-
able at Age and Ageing online). In the majority of cases
(97%) consent was obtained from family members due to
cognitive impairment. Demographic and clinical characteris-
tics were well balanced between groups (Table 1). The
mean age was 88.6 years (SD: 5.6) and 13% had a prior hip
fracture. The majority (87.9%) received surgical treatment
within the first 24 h of admission (range: 0–5 days). Baseline
pain (PAINAD) scored at rest was low 1.4 (SD: 1.7), only 23
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recruits were able to transfer (all with assistance from two
people) and 217 participants were either confined to bed or
transferred using a hydraulic lifter. Almost all showed evi-
dence of cognitive problems with only two people scoring 26
or above on the MMSE. Eighty-four percent (n = 201) of
participants were discharged within 48 h of randomisation.
Of the 240 patients, 186 (77.5%) had a recorded diagnosis of
dementia (further details in Supplementary material, available
at Age and Ageing online).
At 4 weeks, the treatment group achieved a better
mobility score (NHLSD mean difference −1.9; 95% CI:
−3.3 to −0.57; P = 0.0055) (Table 2). The treatment group
also had better nutritional status than the control group
(−0.65; 95% CI: −1.3,−0.05; P = 0.0338).
At 12-month follow-up, the treatment group had better
quality of life as measured by DEMQOL sum scores (mean
difference = −7.4; 95% CI: −12.5, −2.3; P = 0.0051).
There were no other statistically significant differences
between treatment and control groups.
At 4 weeks, the death rate was 8% in the intervention
group and 18% in the control group (log rank test by the
end of 4 weeks P = 0.048), and in the control group the
number of deaths increased each week from one death
(Week 1) to eight deaths (Week 4) (Figure 1). However,
after the rehabilitation program, there was an increase in
deaths in the intervention group. After 35 days, there was
no statistically significant difference between groups in the
probability of survival (Figure 1).
Adverse events
In total, 95 nursing home residents sustained one or more
falls during the 4-week intervention with 56 people from
the intervention group incurring 62.7% (n = 162) of the
falls. Twelve people had hospital admissions including three
hip fractures. In the usual care group, 39 people fell with 15
(38.5%) requiring hospital admission and one person sus-
tained a hip fracture (see Supplementary material, available
at Age and Ageing online).
Economic evaluation
Mean per participant 12-month Australian Medicare costs
were higher in the intervention group than in the control
arm (by $2,076 per patient) but these differences were not
statistically significant (95% CI: −$220–$4,360). Drivers of
higher costs in the intervention were the intervention cost
itself and higher drug costs. When the adjusted 12-month
primary and secondary outcomes in the base case were con-
sidered (Supplementary material), the intervention was
more effective than the control with participants reporting
NHLSD totals scores that were higher by 0.3745 per
patient (95% CI: −1.327 to 2.076) and QALYs gained that
were higher by 0.0063 per patient (95% CI: −0.0547 to
0.0686). The resulting incremental cost effectiveness ratios
(ICERs) were $5,545 per unit increase in the NHLSD total
score (95% CI: $244–$15,159) and $328,685 per QALY
gained (95% CI: $82,654–$75,007,056). The ICER based
on QALYs is substantially greater than the implicit cost-
effectiveness threshold of $50,000 per QALY gained cur-
rently applied by regulatory bodies in Australia [19], imply-
ing that the intervention would not be considered cost-
effective [17].
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Baseline characteristics of study population
Characteristic* Control Intervention
N1 = 121 N2 = 119
Female sex—n (%) 91 (75.2) 87 (73.1)
Age—n (%) (range: 70–101)
70–79 8 (6.6) 8 (6.7)
80–89 56 (46.3) 62 (52.1)
90–95 44 (36.4) 38 (31.9)
>95 13 (10.7) 11 (9.2)
Age-mean (SD) 88.6 (5.7) 88.6 (5.4)
Mini-Mental State Examination—mean (SD) 8.5 (7.6) 7.5 (8.0)
Medication Appropriateness Index—mean (SD) 2.5 (1.9) 2.3 (1.8)
Delirium—n (%) 41 (33.9) 42 (35.3)
Previous any fractures—yes (%) 47 (38.8) 47 (39.5)
Previous hip fractures—yes (%) 16 (13.1) 16 (13.6)
Type of hip of fracture (at baseline)
Extracapsular 58 (47.9) 52 (43.7)
Intracapsular 63 (52.1) 67 (56.3)
Extracapsular hip fracture-surgery type at baseline (n = 110)
Sliding hip screw 8 (13.8) 15 (28.8)
Intramedullary nail 50 (86.2) 37 (71.2)
Intracapsular hip fracture-surgery type at baseline (n = 130)
Internal fixation 18 (28.6) 15 (22.4)
Cemented Hemiarthroplasty 28 (44.4) 36 (53.7)
Uncemented Hemiarthroplasty 15 (23.8) 15 (22.4)
Total hip replacement 2 (3.2) 1 (1.5)
Pre-fracture Mobility Aid indoor
None 20 (16.5) 26 (21.9)
Walking stick 5 (4.1) 2 (1.7)
Walking frame 96 (79.3) 89 (74.8)
Personal assistance 0 (0.0) 2 (1.7)
Pre-fracture Mobility Aid Outdoor
None 15 (12.4) 23 (19.3)
Walking stick 4 (3.3) 1 (0.8)
Walking frame 76 (62.8) 67 (56.3)
Personal assistance 1 (0.8) 3 (2.5)
Unable 25 (20.6) 25 (21.0)
Pre-fracture Mobility Assistance—Indoor
Independent 82 (67.8) 73 (61.3)
1 x LA 16 (13.2) 19 (16.0)
1 x MA 4 (3.3) 7 (5.9)
1 x S/B 19 (15.7) 20 (16.8)
Pre-fracture Mobility Assistance—Outdoor
Independent 41 (33.9) 33 (27.7)
1 x LA 17 (14.1) 18 (15.1)
1 x MA 4 (3.3) 1 (0.8)
1 x S/B 37 (30.6) 35 (29.4)
2 x LA 1 (0.8) 6 (5.0)
Unable 21 (17.4) 26 (21.9)
*There was no significant difference (P < 0.05) between control and interven-
tion groups for all above variables at baseline. Data are mean (SD) or n (%).
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Discussion
A 4-week multidisciplinary home rehabilitation program
reduced mortality and improved mobility and nutritional
status in people living in NCFs who had previously been
walking but then fractured their hips. However,
improvements were not sustained at 12 months. At 12
months, there was a small quality of life improvement in
survivors.
The higher health costs associated with improved mobil-
ity in the intervention group were modest. However, the
12-month cost effectiveness estimates are prohibitively high
at $5,545 per unit improvement in the NHLSD total scores
and $328,685 per QALY gained. Estimates of the incre-
mental costs per QALY gained from this trial are much
higher than the recommended threshold of $50,000/QALY
used in Australia suggesting that providing outreach
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Baseline and four week data for primary and secondary outcomes
Outcomes Control Intervention Difference (95% CI) P value
nc Mean (SE) nc Mean (SE)
Primary outcomes
Baseline
NHLSD 121 0 (0) 119 0 (0) _ _
Quality of life
DEMQOL sum score 50 86.5 (1.2) 40 86.2 (4.4) 0.30 (−3.4, 4.0) 0.8711
DEMQOL index (utility) 50 0.80 (0.04) 40 0.79 (0.04) 0.01 (−0.11, 0.13) 0.8587
DEMQOL-proxy sum score 119 90.9 (1.0) 118 92.1 (1.0) −1.1 (−3.8, 1.6) 0.4141
DEMQOL-proxy index (utility) 119 0.62 (0.02) 118 0.54 (0.02) −0.01 (−0.08, 0.06) 0.7111
EQ5D5L index (utility) 119 0.22 (0.02) 119 0.23 (0.02) −0.01 (−0.08, 0.06) 0.7788
4 Weeks
NHLSD 96 6.3 (0.50) 107 8.2 (0.47) −1.9 (−3.3, −0.57) 0.0055
Quality of life
DEMQOL sum score 45 88.3 (1.6) 49 91.0 (1.7) −2.7 (−7.3, 1.8) 0.2370
DEMQOL index 67 0.68 (0.05) 59 0.74 (0.04) −0.06 (−0.20, 0.08) 0.3896
DEMQOL-proxy sum score 94 93.7 (1.1) 105 94.2 (1.0) −0.52 (−3.5, 2.4) 0.7305
DEMQOL-proxy index 116 0.54 (0.02) 115 0.60 (0.02) −0.06 (−0.11, 0.01) 0.0784
EQ5D5L index 118 0.38 (0.02) 115 0.43 (0.02) −0.05 (−0.12, 0.01) 0.1058
12 Months
NHLSD 66 10.1 (0.60) 60 10.5 (0.63) 0.37 (−2.1, 1.3) 0.6777
Quality of life
DEMQOL sum score 41 88.5 (1.6) 29 95.9 (2.0) −7.4 (−12.5, −2.3) 0.0051
DEMQOL index 93 0.54 (0.03) 87 0.48 (0.04) 0.06 (−0.07, 0.19) 0.3521
DEMQOL-proxy sum score 66 101.9 (1.3) 60 98.7 (1.4) 3.1 (−0.62, 6.9) 0.1023
DEMQOL-proxy index 118 0.40 (0.02) 118 0.34 (0.02) 0.06 (−0.003, 0.13) 0.0628
EQ5D5L index 118 0.30 (0.02) 117 0.24 (0.02) 0.06 (−0.006, 0.13) 0.0739
Secondary outcomes
Baseline
PAINAD 121 1.4 (0.11) 119 1.4 (0.11) 0.00 (−0.31, 0.31) 0.9824
Modified Barthel Index 121 9.6 (1.8) 119 9.5 (1.8) 0.08 (−4.9, 5.1) 0.9735
Cornell Scale for Depression in Dementia 119 10.1 (0.42) 119 10.0 (0.42) 0.01 (−1.2, 1.2) 0.9857
Mini-Nutritional Assessment 121 5.4 (0.20) 119 5.3 (0.20) 0.12 (−0.43, 0.68) 0.6670
Functional recovery 121 1.8 (0.36) 119 1.8 (0.36) 0.01 (−0.98, 1.01) 0.9798
Delirium 121 0.34 (0.04)a 119 0.35 (0.04)a 0.94 (0.55, 1.6)b 0.8184
4 Weeks
PAINAD 95 0.49 (0.13) 107 0.51 (0.12) −0.02 (−0.34, 0.29) 0.8998
Modified Barthel Index 95 23.5 (2.0) 107 24.4 (1.9) −1.0 (−6.4, 4.5) 0.7267
Cornell Scale for Depression in Dementia 96 10.6 (0.47) 107 10.5 (0.44) 0.15 (−1.1, 1.4) 0.8097
Mini-Nutritional Assessment 96 6.2 (0.22) 107 6.9 (0.21) −0.65 (−1.3, −0.05) 0.0338
Functional recovery 94 5.8 (0.40) 107 6.0 (0.38) −0.25 (−1.3, 0.84) 0.6542
Delirium 95 0.13 (0.03) 107 0.17 (0.04) 0.75 (0.35, 1.6) 0.4589
12 Months
PAINAD 66 0.06 (0.15) 60 0.05 (0.16) 0.01 (−0.42, 0.44) 0.9645
Modified Barthel Index 66 32.3 (2.4) 59 27.4 (2.5) 5.0 (−1.9, 11.8) 0.1533
Cornell Scale for Depression in Dementia 66 9.3 (0.56) 60 10.1 (0.59) −0.8 (−2.4, 0.8) 0.3262
Mini-Nutritional Assessment 66 8.0 (0.27) 60 8.8 (0.28) −0.73 (−1.5, 0.03) 0.0592
Functional recovery 66 7.1 (0.48) 60 6.2 (0.50) 0.84 (−0.52, 2.2) 0.2257
Delirium 66 0.18 (0.05)a 60 0.22 (0.05)a 0.77 (0.33, 1.8)b 0.5486
aPercentage.
bodds ratio.
cFor sum scores, deceased patients were treated as missing, for index scores (utility), patients who were deceased were assigned a zero value.
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rehabilitation is not likely to be value for money for a health
service. One option to improve the cost effectiveness esti-
mate would be to decrease the rehabilitation costs and
extend the period of additional therapy by exploring models
of rehabilitation where NCF staff are trained to deliver
therapy for longer periods of time. However, for frail older
people living in nursing homes where death is a common
event and quality of life gains are modest, results of cost
effectiveness approaches are unlikely to be favourable and
decisions on allocation of resources to this group may need
to include consideration of a community’s values. After this
trial, a citizens’ jury process was conducted with randomly
selected citizens which suggested that the community
regards access to recovery or rehabilitation services for
nursing home patients as a human rights issue and despite
the cost effectiveness analysis would allocate health
resources to hip fracture rehabilitation to people in nursing
homes [20].
There are difficulties assessing quality of life in very old
people with dementia. While the DEMQOL and DEMQOL
proxy measures are likely to be accurate measures for quality
of life in people living with dementia, the validity of these
measures in people without dementia is unclear [21]. The
EQ-5D is widely-used in economic evaluations of healthcare
and has high reliability and good validity. However, the valid-
ity of the EQ-5D for people with moderate to severe
dementia is unclear [22].
Our study revealed that people returning to NCFs after
hip fracture receive very little support for recovery and it is
possible that the initial group difference in mortality
resulted from moving and attempting to re-establish mobil-
ity and avoiding complications. The high mortality rate in
hip fracture patients from NCFs has been previously
reported as 45% at 12 months and a combined rate of
death or new inability to ambulate of 63% [23].
As the study was undertaken with participants living in
NCFs who were mobile pre-fracture the results may not be
generalisable to people living in the community or those
who had no mobility pre-fracture. There is some evidence
of an increased rate of adverse events (falls) in the interven-
tion group. This suggests that the intervention should be
applied carefully when trying to re-establish mobility in this
group.
The scoring algorithms we used for the EQ-5D-5L,
DEMQOL and DEMQOL proxy were from a UK general
population sample [24, 25] despite the study taking place in
Australia because Australian scoring algorithms were
unavailable, as utilities. However, health states have been
shown to differ across countries and jurisdictions [26].
Previous studies to investigate the agreement between self-
and proxy-rated HRQoL for people with dementia have
indicated only a poor-to-moderate level of agreement over-
all, with proxy assessors tending to report lower HRQoL
than individuals themselves [27, 28]. The choice of proxy
assessor (e.g. family member, residential care staff member,
clinician) has also previously been found to be associated
with discrepancies in assessment of HRQoL using the EQ-
5D [27, 28]. Despite these shortcomings associated with
the use of proxy rating (and whilst it our collective belief
that self-assessment of HRQoL is preferable where ever
possible), for the conduct of economic evaluation where
assessment of HrQoL is required at repeated time intervals
over an extended time period proxy assessment is likely to
be necessary. As indicated previously, proxy assessment of
HRQoL is the most acceptable across the entire range of
Alzheimer’s disease severity in terms of validity and reliabil-
ity in detecting long-term changes relevant to economic
evaluations [29].
A limitation of our study was that the UK, rather than
Australian, value sets were used to calculate utility scores
for both the DEMQOL and EQ-5D instruments as the lat-
ter is not yet available. Generally, guidelines recommend
using preference weights specific to the jurisdiction of inter-
est as empirical evidence suggests population values may
differ for health states across countries, possibly due to cul-
tural differences [30]. Hence, it is important that future
research employs Australian general population-specific
value sets as these become available.
The current study not only demonstrates the challenges
of working with very old people who have high mortality
rates but also the difficulties in assessing effective treat-
ments and improvements in quality of life.
Conclusions
A rehabilitation program for older people living in NCFs
after hip fracture surgery who were mobile pre-surgery
showed improved mobility, nutritional status and survival
compared to usual care at 4 weeks. These improvements
did not persist at one year but there were small quality of
life gains at 12 months in the survivors. The outreach
rehabilitation program was not cost-effective. Further
studies could investigate whether a longer-term or NCF-
based rehabilitation approach following hip fracture is
cost-effective.
Figure 1. Survival probability from randomisation to 12-
month follow-up.
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Supplementary data mentioned in the text are available to
subscribers in Age and Ageing online.
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Abstract
Background: in chronic kidney disease (CKD), hypertension is associated with poor outcomes at ages <70 years. At older
ages, this association is unclear. We tested 10-year mortality and cardiovascular outcomes by clinical systolic blood pressure
(SBP) in older CKD Stages 3 and 4 patients without diabetes or proteinuria.
Methods: retrospective cohort in population representative primary care electronic medical records linked to hospital data
from the UK. CKD staged by CKD-EPI equation (≥2 creatinine measurements ≥90 days apart). SBPs were 3-year medians
before baseline, with mean follow-up 5.7 years. Cox competing models accounted for mortality.
Results: about 158,713 subjects with CKD3 and 6,611 with CKD4 met inclusion criteria. Mortality increased with increas-
ing CKD stage in all subjects aged >60. In the 70 plus group with SBPs 140–169 mmHg, there was no increase in mortality,
versus SBP 130–139. Similarly, SBPs 140–169 mmHg were not associated with increased incident heart failure, stroke or
myocardial infarctions. SBPs <120 mmHg were associated with increased mortality and cardiovascular risk. At ages 60–69,
there was increased mortality at SBP <120 and SBP >150 mmHg.
Results were little altered after excluding those with declining SBPs during 5 years before baseline, or for longer-term out-
comes (5–10 years after baseline).
Conclusions: in older primary care patients, CKD3 or 4 was the dominant outcome predictor. SBP 140–169 mmHg having
little additional predictive value, <120 mmHg was associated with increased mortality. Prospective studies of representative
older adults with CKD are required to establish optimum BP targets.
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